Keyword: Ultomiris (ravulizumab-cwvz)
Alexion, amidst a strategy shift to pipeline building, has said no to an activist investor's call to pursue a "proactive" sale.
Alexion is working to switch patients from Soliris to its newer Ultomiris.
Alexion is pushing hard to get patients on its blockbuster Soliris over to a follow-up drug, but the older med's sales are still hanging in there.
Alexion's campaign to switch patients from blockbuster Soliris to a follow-up drug has gone according to plan. A new indication will help even more.
Investors are running scared after a patent challenge from Amgen hit Alexion’s bestselling Soliris—but is it that big of a deal?
9. Alexion Pharmaceuticals
Rumors that Amgen could buy Alexion have been floating around for more than a year. Now, they’ve resurfaced, to the delight of Wall Street analysts.
Alexion's plan to switch patients from blockbuster Soliris to newcomer Ultomiris in on track. But why isn't the company's share price reflecting that?
Alexion hopes that a new indication for Soliris will rake in $1 billion over the next 10 years, but spurring uptake could be an issue.
Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from the 2019 class of top drug launches. Instead, treatments in immunology and rare genetic diseases have grabbed the limelight.